Amsterdam, NL, January 29, 2019 – For most of human history Parkinson’s disease (PD) has been a rare disorder. However, demography and the by-products of industrialization are now contributing to an impending Parkinson’s pandemic, according to experts writing in a supplement to the Journal of Parkinson’s Disease. They say that this pandemic can be addressed...
Tag: <span>Parkinson’s disease (PD)</span>
Post
Cognitive status doesn’t impact cortical A-beta, tau in Parkinson’s
(HealthDay)—Patterns of cortical β-amyloid (Aβ) and tau are not different for patients with Parkinson’s disease (PD) who are cognitively normal (PD-CN) or with mild cognitive impairment (MCI) and for healthy adults, according to a study published online Dec. 11 in JAMA Neurology. Joseph R. Winer, from the University of California in Berkeley, and colleagues conducted a...
Post
Tapeworm drug could lead the fight against Parkinson’s disease
Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the Substantia nigra in Parkinson’s disease. Researchers at Cardiff University, in collaboration with the University of Dundee, have identified a drug molecule within a medicine used to treat tapeworm infections which could lead to new treatments for patients with Parkinson’s disease. Parkinson’s...
Post
Low frequency brain stimulation improves cognition in Parkinson’s disease
A multidisciplinary neuroscience study using rare, intraoperative brain recordings suggests that low frequency stimulation of a deep brain region may be able to improve cognitive function in patients with Parkinson’s disease (PD). The study findings, published Nov. 28 online in the journal Brain, also hint at the broader potential of brain stimulation for treating other cognitive...
Post
LRRK2 variants linked to lower age at onset of Parkinson’s
(HealthDay)—The presence of multiple LRRK2 risk variants is associated with a younger age at onset (AAO) of Parkinson’s disease (PD), according to a research letter published online Nov. 13 in JAMA Neurology. Bin Xiao, M.D., Ph.D., from the National Neuroscience Institute in Singapore, and colleagues assessed 1,284 patients with PD for the LRRK2 risk variants S1647T, R1628P, and G2385R. The...